Mitchell & Pahl Private Wealth, LLC Ionis Pharmaceuticals Inc Transaction History

Mitchell & Pahl Private Wealth, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 12, 2024	BUY	$36.45 - $47.7 $165,483 - $216,558	4,540 New	4,540 $216,000
Q4 2023 Feb 08, 2024	SELL	$43.39 - $51.63 $216 - $258	-5 Reduced 0.11%	4,617 $233,000
Q3 2023 Oct 31, 2023	BUY	$38.5 - $47.13 $177,947 - $217,834	4,622 New	4,622 $209,000
Q3 2022 Nov 01, 2022	BUY	$36.54 - $48.66 $177,803 - $236,779	4,866 New	4,866 $215,000
Q2 2022 Jul 25, 2022	SELL	$31.71 - $43.0 $174,056 - $236,027	-5,489 Closed	0 $0
Q1 2022 Apr 14, 2022	BUY	$29.88 - $37.04 $164,011 - $203,312	5,489 New	5,489 $203,000
Q4 2021 Jan 19, 2022	SELL	$25.61 - $35.1 $176,401 - $241,768	-6,888 Closed	0 $0
Q3 2021 Nov 03, 2021	SELL	$33.54 - $40.55 $1,609 - $1,946	-48 Reduced 0.69%	6,888 $231,000
Q2 2021 Jul 14, 2021	SELL	$34.54 - $47.25 $2,383 - $3,260	-69 Reduced 0.99%	6,936 $277,000
Q1 2021 Apr 29, 2021	SELL	$42.51 - $63.78 $680 - $1,020	-16 Reduced 0.23%	7,005 $315,000
Q4 2020 Feb 09, 2021	BUY	$45.3 - $60.27 $318,051 - $423,155	7,021 New	7,021 $397,000

402

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.16B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Mitchell & Pahl Private Wealth, LLC, based on Form 13F filings with the SEC.

Stay updated on Mitchell & Pahl Private Wealth, LLC with notifications on news.